Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2001Antimicrobial Agents and ChemotherapyOpen Access

In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans

View Full Paper
Ask AI
Bookmark
Share

Authors

Michael A. Pfaller
Michael A. PfallerUniversity of VermontSMS. A. MesserJMI LaboratoriesRHR. J. HollisTilganga Institute of Ophthalmology

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pfaller et al. (2001) studied this question.

synapsesocial.com/papers/6a6f6da435aa2c282ce0ca76https://doi.org/10.1128/aac.45.10.2862-2864.2001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole1998 · 128 citations
  2. 2Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia2001 · 179 citations
  3. 3In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida2000 · 110 citations
  4. 4In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens2000 · 80 citations
  5. 5National Committee for Clinical Laboratory Standards1980 · 14,792 citations